Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold
Open Access
- 16 December 2024
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (2) , 345-354
Abstract
Objective: To investigate retinal layer thinning as a biomarker of disease‐modifying treatment (DMT) effects in relapsing multiple sclerosis (RMS).Methods: From an ongoing prospective observational study, we included patients with RMS, who (i) had an optical coherence tomography (OCT) scan within 6 to 12 months after DMT start (rebaseline) and ≥1 follow‐up OCT ≥12 months after rebaseline and (ii) adhered to DMT during follow‐up. Differences between DMT in thinning of peripapillary‐retinal‐nerve‐fiber‐layer (pRNFL) and macular ganglion cell‐plus‐inner plexiform‐layer (GCIPL) were analyzed using mixed‐effects linear regression. Eyes suffering optic neuritis during follow‐up were excluded.Results: We included 291 RMS patients (mean age 30.8 years [SD 7.9], 72.9% female, median disease duration 9 months [range 6–94], median rebaseline‐to‐last‐follow‐up‐interval 32 months [12–82]).Mean annualized rates of retinal layer thinning (%/year) in reference to DMF (n = 84, GCIPL 0.28, pRNFL 0.53) were similar under TERI (n = 18, GCIPL 0.34, pRNFL 0.59), GLAT (n = 24, GCIPL 0.32, pRNFL 0.56), and IFNb (n = 13, GCIPL 0.33, pRNFL 0.60) were slightly lower under S1PM (n = 27, GCIPL 0.19, pRNFL 0.42) and CLA (n = 23, GCIPL 0.20, pRNFL 0.42), and were significantly lower under NTZ (n = 47, GCIPL 0.09, pRNFL 0.24; both p < 0.001) and antiCD20 (n = 55, GCIPL 0.10, pRNFL 0.23; both p < 0.001). In patients achieving NEDA‐2, observed thinning rates were lower overall, but still significantly lower under NTZ and antiCD20.Interpretation: Applying a rebaselining concept, retinal layer thinning differentiates DMT effects even in clinically stable patients and, thus, might be a useful biomarker to monitor DMT efficacy on subclinical neuroaxonal degeneration—at least on a group level.Keywords
This publication has 39 references indexed in Scilit:
- Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter studyAnnals of Clinical and Translational Neurology, 2021
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsJAMA Neurology, 2020
- Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer AtrophyAnnals of Neurology, 2020
- Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international studyAnnals of Neurology, 2019
- Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple SclerosisJAMA Neurology, 2018
- Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple SclerosisJAMA Neurology, 2017
- Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysisJournal of Neurology, 2017
- Effectiveness of averaging strategies to reduce variance in retinal nerve fibre layer thickness measurements using spectral-domain optical coherence tomographyGraefe's Archive for Clinical and Experimental Ophthalmology, 2013
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985